The Fund aims to provide capital growth over the long term.
The Fund invests at least 80% of its assets in shares (equities) and equity-related securities of companies, which are biotechnology or biotechnology-related, in any country.
ABOUT THIS FUND
Experienced and Specialised Investment Team: Dedicated biotechnology specialists with a distinguished record of investing in biotechnology stocks. Team is supported by the larger Janus Henderson health care team.
Differentiated Fundamental Research: Seek to understand the science and the business to identify opportunities and mitigate the clinical and commercial risks inherent in the sector.
Disciplined Investment Process: Balanced across development stage, early commercial and profitable biotechnology companies and augmented by a differentiated Value at Risk Framework designed to mitigate the volatility associated with drug development.